Clinical Trial Next for Laser Technique
!%Carl Zeiss Meditec AG%! of Dublin, Calif., and Jena, Germany, has received conditional approval from the FDA to initiate a clinical trial for its ReLEx smile procedure to correct myopia. The technique for refractive surgery combines femtosecond laser technology and precise lenticule extraction for minimally invasive laser vision correction in a single system, the VisuMax femtosecond laser. In lasik procedures, the excimer laser vaporizes tissue, while the ReLEx smile method generates a refractive lenticule in the intact cornea with the femtosecond laser. The surgeon then removes the lenticule through a small incision without having to move the patient to an excimer laser.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024